Identification

Name
Ceritinib
Accession Number
DB09063
Type
Small Molecule
Groups
Approved
Description

Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

Structure
Thumb
Synonyms
  • céritinib
  • N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
External IDs
LDK 378 / LDK-378 / LDK378 / NVP-LDK378-NX
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZykadiaCapsule150 mgOralNovartis2015-04-29Not applicableCanada
ZykadiaCapsule150 mgOralNovartis Europharm Limited2015-05-06Not applicableEu
ZykadiaCapsule150 mgOralNovartis Europharm Limited2015-05-06Not applicableEu
ZykadiaCapsule150 mg/1OralNovartis2014-04-29Not applicableUs
Categories
UNII
K418KG2GET
CAS number
1032900-25-6
Weight
Average: 558.135
Monoisotopic: 557.22273844
Chemical Formula
C28H36ClN5O3S
InChI Key
VERWOWGGCGHDQE-UHFFFAOYSA-N
InChI
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
IUPAC Name
5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
SMILES
CC(C)OC1=C(NC2=NC=C(Cl)C(N2)=NC2=CC=CC=C2S(=O)(=O)C(C)C)C=C(C)C(=C1)C1CCNCC1

Pharmacology

Indication

Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Ceritinib inhibits Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246 (cluster of differentiation 246), which is an enzyme that in humans is encoded by the ALK gene. About 4-5% of NSCLCs have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Ceritinib has been shown to inhibit in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats.

TargetActionsOrganism
AALK tyrosine kinase receptor
antagonist
Human
Absorption

After oral administration of ceritinib, peak concentrations were achieved after approximately 4 to 6 hours.

Volume of distribution

The apparent volume of distribution (Vd/F) is 4230 L following a single 750 mg dose.

Protein binding

Ceritinib is 97% bound to human plasma proteins, independent of drug concentration.

Metabolism

In vitro studies demonstrated that CYP3A was the major enzyme involved in the metabolic clearance of ceritinib. Following oral administration of a single 750 mg radiolabeled ceritinib dose, ceritinib as the parent compound was the main circulating component (82%) in human plasma.

Route of elimination

Following oral administration of a single 750 mg radiolabeled ceritinib dose, 92.3% of the administered dose was recovered in the feces (with 68% as unchanged parent compound) while 1.3% of the administered dose was recovered in the urine.

Half life

The terminal half life is 41 hours.

Clearance

The geometric mean apparent clearance (CL/F) of ceritinib was lower at steady-state (33.2 L/h) after 750 mg daily dosing than after a single 750 mg dose (88.5 L/h).

Toxicity

There is not currently any data on carcinogenicity, effect on human fertility, or on early embryonic development. However, based on its mechanism of action, ceritinib may cause fetal harm when administered to pregnant women and should therefore be administered with effective contraception during treatment. Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients. Drug-induced hepatotoxicity also occurred in 27% of 255 patients, presenting as alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (ULN). Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis, hyperglycaemia, and bradycardia have also been reported.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Ceritinib.Experimental
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hyperglycemic activities of Ceritinib.Investigational
19-norandrostenedione19-norandrostenedione may increase the hyperglycemic activities of Ceritinib.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Ceritinib.Investigational
5-androstenedione5-androstenedione may increase the hyperglycemic activities of Ceritinib.Experimental, Illicit
AbemaciclibThe risk or severity of adverse effects can be increased when Ceritinib is combined with Abemaciclib.Approved, Investigational
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Ceritinib.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ceritinib.Approved, Investigational
AcebutololAcebutolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
AceclofenacThe serum concentration of Aceclofenac can be increased when it is combined with Ceritinib.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Ceritinib.Approved, Investigational
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ceritinib.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ceritinib.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe serum concentration of Acetyl sulfisoxazole can be increased when it is combined with Ceritinib.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ceritinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ceritinib.Experimental
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ceritinib.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Ceritinib.Approved
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Ceritinib.Experimental, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Ceritinib.Experimental, Investigational
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Ceritinib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Ceritinib.Approved
AldosteroneAldosterone may increase the hyperglycemic activities of Ceritinib.Experimental, Investigational
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Ceritinib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ceritinib.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Ceritinib.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Ceritinib.Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Ceritinib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Ceritinib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Ceritinib.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Ceritinib.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be increased when it is combined with Ceritinib.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Ceritinib.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ceritinib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Ceritinib.Approved, Investigational
AmcinonideAmcinonide may increase the hyperglycemic activities of Ceritinib.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Ceritinib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Ceritinib.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Ceritinib.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ceritinib.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Ceritinib.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ceritinib.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Ceritinib.Approved, Investigational
AnagrelideCeritinib may increase the QTc-prolonging activities of Anagrelide.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Ceritinib.Approved, Investigational, Withdrawn
AndrostenedioneAndrostenedione may increase the hyperglycemic activities of Ceritinib.Experimental, Illicit
AnecortaveAnecortave may increase the hyperglycemic activities of Ceritinib.Investigational
anecortave acetateanecortave acetate may increase the hyperglycemic activities of Ceritinib.Investigational
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Ceritinib.Approved, Investigational
ApalutamideThe serum concentration of Ceritinib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ceritinib.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Ceritinib.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Ceritinib.Approved, Investigational
Arachidonic AcidThe serum concentration of Arachidonic Acid can be increased when it is combined with Ceritinib.Experimental
AranidipineThe serum concentration of Aranidipine can be increased when it is combined with Ceritinib.Approved, Investigational
ArformoterolThe serum concentration of Arformoterol can be increased when it is combined with Ceritinib.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Ceritinib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.Approved, Investigational
Arsenic trioxideCeritinib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Ceritinib.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Ceritinib.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Ceritinib.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
AtamestaneAtamestane may increase the hyperglycemic activities of Ceritinib.Investigational
AtazanavirThe serum concentration of Ceritinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the bradycardic activities of Ceritinib.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ceritinib.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ceritinib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Ceritinib.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Ceritinib.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ceritinib.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Ceritinib.Approved
AzelnidipineThe serum concentration of Azelnidipine can be increased when it is combined with Ceritinib.Approved, Investigational
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Ceritinib.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ceritinib.Investigational
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Ceritinib.Investigational
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Ceritinib.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Ceritinib.Approved
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ceritinib.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Ceritinib.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Ceritinib.Investigational
BencyclaneThe serum concentration of Bencyclane can be increased when it is combined with Ceritinib.Experimental
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Ceritinib.Approved
BenidipineThe serum concentration of Benidipine can be increased when it is combined with Ceritinib.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ceritinib.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Ceritinib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Ceritinib.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Ceritinib.Approved, Withdrawn
BeractantBeractant may increase the bradycardic activities of Ceritinib.Approved
BetamethasoneBetamethasone may increase the hyperglycemic activities of Ceritinib.Approved, Vet Approved
BetaxololBetaxolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Ceritinib.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Ceritinib.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Ceritinib.Approved, Investigational
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Ceritinib.Approved
BictegravirThe serum concentration of Bictegravir can be increased when it is combined with Ceritinib.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be increased when it is combined with Ceritinib.Approved, Experimental
BisoprololBisoprolol may increase the bradycardic activities of Ceritinib.Approved
BlonanserinThe serum concentration of Blonanserin can be increased when it is combined with Ceritinib.Approved, Investigational
BoceprevirThe serum concentration of Ceritinib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Ceritinib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ceritinib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ceritinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ceritinib.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Ceritinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ceritinib.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Ceritinib.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Ceritinib.Approved
BrivaracetamThe serum concentration of Brivaracetam can be increased when it is combined with Ceritinib.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ceritinib.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Ceritinib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ceritinib.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ceritinib.Investigational, Withdrawn
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Ceritinib.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Ceritinib.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Ceritinib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Ceritinib.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ceritinib.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ceritinib.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Ceritinib.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ceritinib.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Ceritinib.Approved, Nutraceutical
CalfactantCalfactant may increase the bradycardic activities of Ceritinib.Approved
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ceritinib.Approved
CandesartanThe serum concentration of Candesartan can be increased when it is combined with Ceritinib.Experimental
Candesartan cilexetilThe serum concentration of Candesartan cilexetil can be increased when it is combined with Ceritinib.Approved
CannabidiolThe serum concentration of Cannabidiol can be increased when it is combined with Ceritinib.Approved, Investigational
CarbamazepineThe serum concentration of Ceritinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Ceritinib.Approved
CarboxyamidotriazoleThe serum concentration of Carboxyamidotriazole can be increased when it is combined with Ceritinib.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Ceritinib.Experimental
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Ceritinib.Approved, Investigational
CaroverineThe serum concentration of Caroverine can be increased when it is combined with Ceritinib.Experimental
CarteololCarteolol may increase the bradycardic activities of Ceritinib.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Ceritinib.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ceritinib.Experimental
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Ceritinib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Ceritinib.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ceritinib.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ceritinib.Approved
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Ceritinib.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Ceritinib.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Ceritinib.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Ceritinib.Approved, Investigational
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Ceritinib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Ceritinib.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Ceritinib.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ceritinib.Experimental
CilnidipineThe serum concentration of Cilnidipine can be increased when it is combined with Ceritinib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ceritinib.Approved, Investigational
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Ceritinib.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Ceritinib.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ceritinib.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe serum concentration of Ceritinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Ceritinib is combined with Clemastine.Approved, Investigational
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Ceritinib.Approved, Investigational
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Ceritinib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ceritinib.Approved, Illicit
ClobetasolClobetasol may increase the hyperglycemic activities of Ceritinib.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hyperglycemic activities of Ceritinib.Approved
ClobetasoneClobetasone may increase the hyperglycemic activities of Ceritinib.Approved
ClocortoloneClocortolone may increase the hyperglycemic activities of Ceritinib.Approved
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Ceritinib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Ceritinib.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Ceritinib.Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Ceritinib.Approved, Illicit
ClonidineClonidine may increase the bradycardic activities of Ceritinib.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ceritinib.Approved
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Ceritinib.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Ceritinib.Approved, Illicit
ClotrimazoleThe serum concentration of Ceritinib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ceritinib.Approved
CobicistatThe serum concentration of Ceritinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ceritinib.Approved, Investigational
CocaineThe serum concentration of Cocaine can be increased when it is combined with Ceritinib.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Ceritinib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ceritinib.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ceritinib.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Ceritinib.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Ceritinib.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hyperglycemic activities of Ceritinib.Investigational
CorticosteroneCorticosterone may increase the hyperglycemic activities of Ceritinib.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Ceritinib.Approved, Investigational
CrizotinibCrizotinib may increase the bradycardic activities of Ceritinib.Approved
CurcuminThe serum concentration of Ceritinib can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe serum concentration of Cyclandelate can be increased when it is combined with Ceritinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Ceritinib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Ceritinib.Experimental
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Ceritinib.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ceritinib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Ceritinib.Approved, Investigational
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Ceritinib.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ceritinib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Ceritinib.Investigational
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Ceritinib.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Ceritinib.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be increased when it is combined with Ceritinib.Experimental
DarunavirThe serum concentration of Ceritinib can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Ceritinib.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Ceritinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ceritinib.Approved
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Ceritinib.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Ceritinib.Approved
DelamanidCeritinib may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Ceritinib.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ceritinib.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Ceritinib.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ceritinib.Approved
DesonideDesonide may increase the hyperglycemic activities of Ceritinib.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hyperglycemic activities of Ceritinib.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hyperglycemic activities of Ceritinib.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hyperglycemic activities of Ceritinib.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Ceritinib.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be increased when it is combined with Ceritinib.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hyperglycemic activities of Ceritinib.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ceritinib.Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Ceritinib.Approved
DexlansoprazoleThe serum concentration of Dexlansoprazole can be increased when it is combined with Ceritinib.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Ceritinib.Approved, Vet Approved
DexniguldipineThe serum concentration of Dexniguldipine can be increased when it is combined with Ceritinib.Experimental
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Ceritinib.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe serum concentration of Dexverapamil can be increased when it is combined with Ceritinib.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Ceritinib.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Ceritinib.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Ceritinib.Approved
DiflorasoneDiflorasone may increase the hyperglycemic activities of Ceritinib.Approved
DifluocortoloneDifluocortolone may increase the hyperglycemic activities of Ceritinib.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hyperglycemic activities of Ceritinib.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ceritinib.Approved, Investigational
DigoxinDigoxin may increase the bradycardic activities of Ceritinib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ceritinib.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be increased when it is combined with Ceritinib.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Ceritinib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ceritinib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ceritinib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ceritinib.Experimental
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ceritinib.Approved, Investigational
DiltiazemDiltiazem may increase the bradycardic activities of Ceritinib.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Ceritinib is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ceritinib.Approved, Investigational
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Ceritinib.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Ceritinib.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ceritinib.Approved, Investigational
DoconexentThe serum concentration of Doconexent can be increased when it is combined with Ceritinib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ceritinib.Approved, Investigational
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Ceritinib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Ceritinib.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Ceritinib.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Ceritinib.Approved
DotarizineThe serum concentration of Dotarizine can be increased when it is combined with Ceritinib.Investigational
DoxazosinThe serum concentration of Ceritinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ceritinib.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ceritinib.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ceritinib.Approved, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ceritinib.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Ceritinib.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Ceritinib.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Ceritinib.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ceritinib.Approved, Investigational
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Ceritinib.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Ceritinib.Approved, Investigational
EfonidipineThe serum concentration of Efonidipine can be increased when it is combined with Ceritinib.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Ceritinib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ceritinib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ceritinib.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Ceritinib.Approved
EmopamilThe serum concentration of Emopamil can be increased when it is combined with Ceritinib.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Ceritinib.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Ceritinib.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Ceritinib.Experimental
EnzalutamideThe serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe serum concentration of Eperisone can be increased when it is combined with Ceritinib.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ceritinib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Ceritinib.Approved
EpoprostenolThe serum concentration of Epoprostenol can be increased when it is combined with Ceritinib.Approved
EquileninEquilenin may increase the hyperglycemic activities of Ceritinib.Experimental
EquilinEquilin may increase the hyperglycemic activities of Ceritinib.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Ceritinib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ceritinib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ceritinib.Approved
EribulinEribulin may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ceritinib.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Ceritinib.Approved, Investigational
EsmololEsmolol may increase the bradycardic activities of Ceritinib.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Ceritinib.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Ceritinib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Ceritinib.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be increased when it is combined with Ceritinib.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ceritinib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Ceritinib.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Ceritinib.Approved, Investigational
EthanolThe serum concentration of Ethanol can be increased when it is combined with Ceritinib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ceritinib.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Ceritinib.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Ceritinib.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Ceritinib.Approved
EtodolacThe serum concentration of Etodolac can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Ceritinib.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ceritinib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Ceritinib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Ceritinib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ceritinib.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Ceritinib.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Ceritinib.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Ceritinib.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ceritinib.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Ceritinib.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Ceritinib.Approved, Investigational
FendilineThe serum concentration of Fendiline can be increased when it is combined with Ceritinib.Withdrawn
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Ceritinib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ceritinib.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Ceritinib.Approved
FingolimodFingolimod may increase the bradycardic activities of Ceritinib.Approved, Investigational
Fish oilThe serum concentration of Fish oil can be increased when it is combined with Ceritinib.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Ceritinib.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ceritinib.Approved, Investigational
FluasteroneFluasterone may increase the hyperglycemic activities of Ceritinib.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
FludrocortisoneFludrocortisone may increase the hyperglycemic activities of Ceritinib.Approved, Investigational
FlumethasoneFlumethasone may increase the hyperglycemic activities of Ceritinib.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Ceritinib.Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Ceritinib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Ceritinib.Approved, Illicit
Fluocinolone AcetonideFluocinolone Acetonide may increase the hyperglycemic activities of Ceritinib.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hyperglycemic activities of Ceritinib.Approved, Investigational
FluocortoloneFluocortolone may increase the hyperglycemic activities of Ceritinib.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Ceritinib.Approved, Investigational
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Ceritinib.Approved, Vet Approved
FlupentixolCeritinib may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluprednideneFluprednidene may increase the hyperglycemic activities of Ceritinib.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hyperglycemic activities of Ceritinib.Approved
FlurandrenolideFlurandrenolide may increase the hyperglycemic activities of Ceritinib.Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of Flurbiprofen can be increased when it is combined with Ceritinib.Approved, Investigational
FluspirileneThe serum concentration of Fluspirilene can be increased when it is combined with Ceritinib.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Ceritinib.Approved, Investigational
FluticasoneFluticasone may increase the hyperglycemic activities of Ceritinib.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ceritinib.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Ceritinib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ceritinib.Approved
FluvoxamineThe serum concentration of Ceritinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneFormestane may increase the hyperglycemic activities of Ceritinib.Approved, Investigational, Withdrawn
FormoterolThe serum concentration of Formoterol can be increased when it is combined with Ceritinib.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Ceritinib.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ceritinib.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be increased when it is combined with Ceritinib.Approved
FosphenytoinThe serum concentration of Ceritinib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of Fostamatinib can be increased when it is combined with Ceritinib.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Ceritinib.Approved, Investigational
GabapentinThe serum concentration of Gabapentin can be increased when it is combined with Ceritinib.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Ceritinib.Approved
GallopamilThe serum concentration of Gallopamil can be increased when it is combined with Ceritinib.Investigational
GavestinelThe serum concentration of Gavestinel can be increased when it is combined with Ceritinib.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ceritinib.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Ceritinib.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ceritinib.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ceritinib.Investigational, Withdrawn
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Ceritinib.Approved
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Ceritinib.Approved
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Ceritinib.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ceritinib.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Ceritinib.Approved
GlycerinThe serum concentration of Ceritinib can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Ceritinib.Approved
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Ceritinib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ceritinib.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
GuanfacineGuanfacine may increase the bradycardic activities of Ceritinib.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ceritinib.Investigational
HalcinonideHalcinonide may increase the hyperglycemic activities of Ceritinib.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Ceritinib.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Ceritinib.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Ceritinib.Approved, Vet Approved
HE3286HE3286 may increase the hyperglycemic activities of Ceritinib.Investigational
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Ceritinib.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Ceritinib.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Ceritinib.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Ceritinib.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ceritinib.Approved, Vet Approved
Hydrocortisone acetateThe serum concentration of Hydrocortisone acetate can be increased when it is combined with Ceritinib.Approved, Vet Approved
Hydrocortisone butyrateThe serum concentration of Hydrocortisone butyrate can be increased when it is combined with Ceritinib.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Ceritinib.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Ceritinib.Approved, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ceritinib.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ceritinib.Approved
IbutilideCeritinib may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe serum concentration of Icotinib can be increased when it is combined with Ceritinib.Approved, Investigational
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Ceritinib.Approved
IdelalisibThe serum concentration of Ceritinib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Ceritinib.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ceritinib.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ceritinib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Ceritinib.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ceritinib.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Ceritinib.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ceritinib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Ceritinib.Approved
IndinavirThe serum concentration of Ceritinib can be increased when it is combined with Indinavir.Approved
IndisulamThe serum concentration of Indisulam can be increased when it is combined with Ceritinib.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ceritinib.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ceritinib.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ceritinib.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ceritinib.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ceritinib.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Ceritinib.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ceritinib.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ceritinib.Approved
IpecacThe serum concentration of Ipecac can be increased when it is combined with Ceritinib.Approved, Withdrawn
IpratropiumThe serum concentration of Ipratropium can be increased when it is combined with Ceritinib.Approved
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Ceritinib.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ceritinib.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be increased when it is combined with Ceritinib.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Ceritinib.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ceritinib.Approved, Vet Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Ceritinib.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ceritinib.Approved
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Ceritinib.Approved, Investigational
IstaroximeIstaroxime may increase the hyperglycemic activities of Ceritinib.Investigational
ItraconazoleThe serum concentration of Ceritinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the bradycardic activities of Ceritinib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Ceritinib.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Ceritinib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Ceritinib.Approved, Investigational
KetamineThe serum concentration of Ketamine can be increased when it is combined with Ceritinib.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ceritinib.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Ceritinib.Approved, Investigational
KetoconazoleThe serum concentration of Ceritinib can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be increased when it is combined with Ceritinib.Approved, Vet Approved
LabetalolLabetalol may increase the bradycardic activities of Ceritinib.Approved
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Ceritinib.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Ceritinib.Approved
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ceritinib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ceritinib.Experimental
LanreotideLanreotide may increase the bradycardic activities of Ceritinib.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ceritinib.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Ceritinib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Ceritinib.Investigational
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Ceritinib.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ceritinib.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Ceritinib.Approved, Investigational
LesinuradThe serum concentration of Lesinurad can be increased when it is combined with Ceritinib.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Ceritinib.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ceritinib.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Ceritinib.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Ceritinib.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Ceritinib.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ceritinib.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ceritinib.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Ceritinib.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Ceritinib.Approved
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Ceritinib.Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Ceritinib.Approved, Vet Approved
LidoflazineThe serum concentration of Lidoflazine can be increased when it is combined with Ceritinib.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Ceritinib.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ceritinib.Approved
LisurideThe serum concentration of Lisuride can be increased when it is combined with Ceritinib.Approved, Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Ceritinib.Experimental
LomerizineThe serum concentration of Lomerizine can be increased when it is combined with Ceritinib.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ceritinib.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ceritinib.Approved
LopinavirThe serum concentration of Ceritinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Ceritinib.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Ceritinib.Approved
LornoxicamThe serum concentration of Lornoxicam can be increased when it is combined with Ceritinib.Approved, Investigational
LorpiprazoleThe serum concentration of Lorpiprazole can be increased when it is combined with Ceritinib.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Ceritinib.Approved
LoteprednolLoteprednol may increase the hyperglycemic activities of Ceritinib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ceritinib.Approved, Investigational
LucinactantLucinactant may increase the bradycardic activities of Ceritinib.Approved, Investigational
LumacaftorThe serum concentration of Ceritinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Ceritinib.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Ceritinib.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ceritinib.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ceritinib.Illicit, Investigational, Withdrawn
MacimorelinThe serum concentration of Macimorelin can be increased when it is combined with Ceritinib.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Ceritinib.Approved
Magnesium sulfateThe serum concentration of Magnesium sulfate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
ManidipineThe serum concentration of Manidipine can be increased when it is combined with Ceritinib.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Ceritinib.Approved, Investigational
ME-609ME-609 may increase the hyperglycemic activities of Ceritinib.Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Ceritinib.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be increased when it is combined with Ceritinib.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ceritinib.Approved, Investigational
MedrysoneMedrysone may increase the hyperglycemic activities of Ceritinib.Approved
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Ceritinib.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Ceritinib.Approved, Investigational
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Ceritinib.Approved, Nutraceutical, Vet Approved
MelengestrolMelengestrol may increase the hyperglycemic activities of Ceritinib.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Ceritinib.Approved, Vet Approved
MentholThe serum concentration of Menthol can be increased when it is combined with Ceritinib.Approved
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Ceritinib.Investigational, Withdrawn
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ceritinib.Approved, Vet Approved
MestranolThe serum concentration of Mestranol can be increased when it is combined with Ceritinib.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ceritinib.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.Approved
MethadoneThe serum concentration of Methadone can be increased when it is combined with Ceritinib.Approved
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Ceritinib.Illicit, Withdrawn
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Ceritinib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
MethyldopaMethyldopa may increase the bradycardic activities of Ceritinib.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ceritinib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Ceritinib.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ceritinib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ceritinib.Experimental
MetipranololMetipranolol may increase the bradycardic activities of Ceritinib.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ceritinib.Approved, Investigational
MetoprololMetoprolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Ceritinib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ceritinib.Experimental
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Ceritinib.Approved, Investigational
MianserinThe serum concentration of Mianserin can be increased when it is combined with Ceritinib.Approved, Investigational
MibefradilThe serum concentration of Ceritinib can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ceritinib.Approved, Illicit
MidecamycinThe serum concentration of Midecamycin can be increased when it is combined with Ceritinib.Approved
MidostaurinThe serum concentration of Midostaurin can be increased when it is combined with Ceritinib.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Ceritinib.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ceritinib.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ceritinib.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ceritinib.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ceritinib.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ceritinib.Approved, Investigational
MitotaneThe serum concentration of Ceritinib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe serum concentration of Moclobemide can be increased when it is combined with Ceritinib.Approved, Investigational
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Ceritinib.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Ceritinib.Approved
MometasoneMometasone may increase the hyperglycemic activities of Ceritinib.Approved, Vet Approved
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Ceritinib.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Ceritinib.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ceritinib.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ceritinib.Approved, Investigational
NabiximolsThe serum concentration of Nabiximols can be increased when it is combined with Ceritinib.Approved, Investigational
NadololNadolol may increase the bradycardic activities of Ceritinib.Approved
NaftopidilThe serum concentration of Naftopidil can be increased when it is combined with Ceritinib.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ceritinib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ceritinib.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Ceritinib.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Ceritinib.Approved, Investigational
NCX 1022NCX 1022 may increase the hyperglycemic activities of Ceritinib.Investigational
NebivololNebivolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
NefazodoneThe serum concentration of Ceritinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ceritinib can be increased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Neratinib can be increased when it is combined with Ceritinib.Approved, Investigational
NetupitantThe serum concentration of Netupitant can be increased when it is combined with Ceritinib.Approved, Investigational
NevirapineThe serum concentration of Ceritinib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ceritinib.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ceritinib.Approved, Investigational
NiclosamideThe serum concentration of Niclosamide can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Ceritinib.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ceritinib.Approved
NiguldipineThe serum concentration of Niguldipine can be increased when it is combined with Ceritinib.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ceritinib.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be increased when it is combined with Ceritinib.Experimental
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Ceritinib.Approved, Investigational
NimesulideThe serum concentration of Nimesulide can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ceritinib.Approved, Investigational
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Ceritinib.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Ceritinib.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Ceritinib.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Ceritinib.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ceritinib.Approved
NylidrinThe serum concentration of Nylidrin can be increased when it is combined with Ceritinib.Approved
OctreotideOctreotide may increase the bradycardic activities of Ceritinib.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Ceritinib.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Ceritinib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Ceritinib.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hyperglycemic activities of Ceritinib.Investigational
OlodaterolThe serum concentration of Olodaterol can be increased when it is combined with Ceritinib.Approved
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Ceritinib.Approved
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Ceritinib.Approved
OpiumThe serum concentration of Opium can be increased when it is combined with Ceritinib.Approved, Illicit
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Ceritinib.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Ceritinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Ceritinib.Approved, Investigational
OtiloniumThe serum concentration of Otilonium can be increased when it is combined with Ceritinib.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ceritinib.Approved
OxaprozinThe serum concentration of Oxaprozin can be increased when it is combined with Ceritinib.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Ceritinib.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Ceritinib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Ceritinib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Ceritinib.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ceritinib.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Ceritinib.Approved, Investigational
PaliperidoneCeritinib may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Ceritinib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ceritinib.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Ceritinib.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Ceritinib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Ceritinib.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Ceritinib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Ceritinib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Ceritinib.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Ceritinib.Approved, Investigational
PasireotidePasireotide may increase the bradycardic activities of Ceritinib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ceritinib.Approved
PenbutololPenbutolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
PenfluridolThe serum concentration of Penfluridol can be increased when it is combined with Ceritinib.Experimental
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Ceritinib.Approved, Investigational
PentobarbitalThe serum concentration of Ceritinib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Ceritinib.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Ceritinib.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Ceritinib.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Ceritinib.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be increased when it is combined with Ceritinib.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Ceritinib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ceritinib.Experimental
PethidineThe serum concentration of Pethidine can be increased when it is combined with Ceritinib.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Ceritinib.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ceritinib.Approved, Investigational, Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ceritinib.Approved
PhenobarbitalThe serum concentration of Ceritinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Ceritinib.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Ceritinib.Approved, Investigational
PhenylbutazoneThe serum concentration of Phenylbutazone can be increased when it is combined with Ceritinib.Approved, Vet Approved
PhenytoinThe serum concentration of Ceritinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Ceritinib.Approved, Investigational
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Ceritinib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ceritinib.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Ceritinib.Approved
PinaveriumThe serum concentration of Pinaverium can be increased when it is combined with Ceritinib.Approved
PindololPindolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Ceritinib.Approved, Investigational
PiperaquineThe serum concentration of Piperaquine can be increased when it is combined with Ceritinib.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Ceritinib.Approved, Investigational
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Ceritinib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ceritinib.Approved
PitolisantThe serum concentration of Ceritinib can be decreased when it is combined with Pitolisant.Approved, Investigational
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Ceritinib.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ceritinib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ceritinib.Approved, Investigational
Poractant alfaPoractant alfa may increase the bradycardic activities of Ceritinib.Approved
PosaconazoleThe serum concentration of Ceritinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ceritinib.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Ceritinib.Approved, Investigational
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Ceritinib.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hyperglycemic activities of Ceritinib.Investigational
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Ceritinib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ceritinib.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Ceritinib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
PrednicarbatePrednicarbate may increase the hyperglycemic activities of Ceritinib.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ceritinib.Approved, Vet Approved
PregabalinThe serum concentration of Pregabalin can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational
PregnenolonePregnenolone may increase the hyperglycemic activities of Ceritinib.Approved, Experimental, Investigational
PrenylamineThe serum concentration of Prenylamine can be increased when it is combined with Ceritinib.Withdrawn
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Ceritinib.Approved
PrimidoneThe serum concentration of Ceritinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideCeritinib may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Ceritinib.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ceritinib.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Ceritinib.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Ceritinib.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Ceritinib.Approved, Investigational
PropafenonePropafenone may increase the bradycardic activities of Ceritinib.Approved
PropiverineThe serum concentration of Propiverine can be increased when it is combined with Ceritinib.Approved, Investigational
PropofolThe serum concentration of Propofol can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the bradycardic activities of Ceritinib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ceritinib.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ceritinib.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Ceritinib.Approved, Investigational
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Ceritinib.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ceritinib.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Ceritinib.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ceritinib.Approved, Investigational
QuinineThe serum concentration of Quinine can be increased when it is combined with Ceritinib.Approved
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Ceritinib.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Ceritinib.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Ceritinib.Approved, Investigational
RanitidineThe serum concentration of Ceritinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ceritinib.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Ceritinib.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ceritinib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Ceritinib.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Ceritinib.Approved
RibociclibThe serum concentration of Ribociclib can be increased when it is combined with Ceritinib.Approved, Investigational
RifabutinThe serum concentration of Ceritinib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Ceritinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ceritinib can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ceritinib.Approved
RimexoloneRimexolone may increase the hyperglycemic activities of Ceritinib.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Ceritinib.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ceritinib.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Ceritinib.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Ceritinib.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ceritinib.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Ceritinib.Approved, Investigational
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Ceritinib.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ceritinib.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Ceritinib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Ceritinib.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Ceritinib.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ceritinib.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Ceritinib.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Ceritinib.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be increased when it is combined with Ceritinib.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Ceritinib.Approved
SafinamideThe serum concentration of Safinamide can be increased when it is combined with Ceritinib.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ceritinib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ceritinib.Approved
SaquinavirThe serum concentration of Ceritinib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Ceritinib.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
SeletracetamThe serum concentration of Seletracetam can be increased when it is combined with Ceritinib.Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ceritinib.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Ceritinib.Approved
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Ceritinib.Approved
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Ceritinib.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ceritinib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ceritinib.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ceritinib.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ceritinib.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ceritinib.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ceritinib.Approved, Investigational
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Ceritinib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Ceritinib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ceritinib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Ceritinib.Investigational
SotalolSotalol may increase the bradycardic activities of Ceritinib.Approved
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Ceritinib.Approved
St. John's WortThe serum concentration of Ceritinib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ceritinib can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the bradycardic activities of Ceritinib.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Ceritinib.Approved
SulfamoxoleThe serum concentration of Sulfamoxole can be increased when it is combined with Ceritinib.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Ceritinib.Approved
SulfisoxazoleThe serum concentration of Sulfisoxazole can be increased when it is combined with Ceritinib.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ceritinib.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Ceritinib.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be increased when it is combined with Ceritinib.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Ceritinib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Ceritinib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Ceritinib.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ceritinib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Ceritinib.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ceritinib.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Ceritinib.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be increased when it is combined with Ceritinib.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Ceritinib.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Ceritinib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Ceritinib.Experimental
TelaprevirThe serum concentration of Ceritinib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Ceritinib.Approved
TelithromycinThe serum concentration of Ceritinib can be increased when it is combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Ceritinib.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ceritinib.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Ceritinib.Approved
TenoxicamThe serum concentration of Tenoxicam can be increased when it is combined with Ceritinib.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ceritinib.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ceritinib.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ceritinib.Experimental
TerodilineThe serum concentration of Terodiline can be increased when it is combined with Ceritinib.Experimental
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Ceritinib.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Ceritinib.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be increased when it is combined with Ceritinib.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be increased when it is combined with Ceritinib.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be increased when it is combined with Ceritinib.Approved, Investigational
TetrabenazineCeritinib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Ceritinib.Approved, Vet Approved
TetrahydropalmatineThe serum concentration of Tetrahydropalmatine can be increased when it is combined with Ceritinib.Investigational
TetrandrineThe serum concentration of Tetrandrine can be increased when it is combined with Ceritinib.Experimental
TezacaftorThe serum concentration of Tezacaftor can be increased when it is combined with Ceritinib.Approved, Investigational
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Ceritinib.Approved
ThiamylalThe serum concentration of Thiamylal can be increased when it is combined with Ceritinib.Approved, Vet Approved
ThioridazineCeritinib may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Ceritinib.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ceritinib.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Ceritinib.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ceritinib resulting in a loss in efficacy.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Ceritinib.Approved
TimololTimolol may increase the bradycardic activities of Ceritinib.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Ceritinib.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Ceritinib.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Ceritinib.Approved, Investigational
TixocortolTixocortol may increase the hyperglycemic activities of Ceritinib.Approved, Withdrawn
TizanidineTizanidine may increase the bradycardic activities of Ceritinib.Approved, Investigational
TocofersolanThe serum concentration of Tocofersolan can be increased when it is combined with Ceritinib.Approved
TocopherolThe serum concentration of Tocopherol can be increased when it is combined with Ceritinib.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Ceritinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ceritinib.Approved, Investigational
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Ceritinib.Approved, Investigational
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be increased when it is combined with Ceritinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Ceritinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ceritinib.Approved
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Ceritinib.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Ceritinib is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ceritinib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Ceritinib.Approved, Investigational
TranilastThe serum concentration of Tranilast can be increased when it is combined with Ceritinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ceritinib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Ceritinib.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Ceritinib.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Ceritinib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Ceritinib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Ceritinib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ceritinib.Approved, Investigational
TrimebutineThe serum concentration of Trimebutine can be increased when it is combined with Ceritinib.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Ceritinib.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Ceritinib.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ceritinib.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ceritinib.Approved, Vet Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Ceritinib.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Ceritinib.Approved
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Ceritinib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ceritinib.Approved
UlobetasolUlobetasol may increase the hyperglycemic activities of Ceritinib.Approved
ValbenazineThe serum concentration of Valbenazine can be increased when it is combined with Ceritinib.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Ceritinib.Approved, Investigational
ValsartanThe serum concentration of Valsartan can be increased when it is combined with Ceritinib.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Ceritinib.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Ceritinib.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Ceritinib.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Ceritinib.Approved, Investigational
VemurafenibThe serum concentration of Ceritinib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ceritinib.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ceritinib.Approved
VerapamilVerapamil may increase the bradycardic activities of Ceritinib.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Ceritinib.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Ceritinib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ceritinib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ceritinib.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ceritinib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ceritinib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ceritinib.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Ceritinib.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Ceritinib.Approved, Investigational
VinpocetineThe serum concentration of Vinpocetine can be increased when it is combined with Ceritinib.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ceritinib.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ceritinib.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Ceritinib.Approved
VoriconazoleThe serum concentration of Ceritinib can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Ceritinib.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Ceritinib.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Ceritinib.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Ceritinib.Approved
WIN 55212-2The serum concentration of WIN 55212-2 can be increased when it is combined with Ceritinib.Experimental
XimelagatranThe serum concentration of Ximelagatran can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Ceritinib.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Ceritinib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Ceritinib.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Ceritinib.Approved, Illicit, Investigational
ZaltoprofenThe serum concentration of Zaltoprofen can be increased when it is combined with Ceritinib.Approved, Investigational
ZiconotideThe serum concentration of Ziconotide can be increased when it is combined with Ceritinib.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ceritinib.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Ceritinib.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Ceritinib.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Ceritinib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Ceritinib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Ceritinib.Approved
ZotepineThe serum concentration of Zotepine can be increased when it is combined with Ceritinib.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Ceritinib.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. Pubmed

General References
  1. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107. [PubMed:24670165]
  2. Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T: Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors. J Thorac Oncol. 2015 Jul;10(7):1058-66. doi: 10.1097/JTO.0000000000000566. [PubMed:26020125]
  3. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21. [PubMed:17185414]
  4. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. [PubMed:23742252]
  5. Mano H: The EML4-ALK oncogene: targeting an essential growth driver in human cancer. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(5):193-201. doi: 10.2183/pjab.91.193. [PubMed:25971657]
External Links
KEGG Drug
D10551
PubChem Compound
57379345
PubChem Substance
310264998
ChemSpider
29315053
BindingDB
50436850
ChEBI
78432
ChEMBL
CHEMBL2403108
HET
4MK
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ceritinib
ATC Codes
L01XE28 — Ceritinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
4mkc
FDA label
Download (307 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingNot AvailableGlioblastomas / Metastatic Brain Tumors1
1Active Not RecruitingTreatmentAnaplastic Lymphoma Kinase / Anaplastic Lymphoma Kinase (ALK)1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedBasic ScienceTumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)1
1CompletedOtherALK-positive Advanced Tumors1
1CompletedTreatmentAnaplastic Lymphoma Kinase (ALK) / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentImpaired Hepatic Function / Normal Hepatic Function1
1CompletedTreatmentTumors Characterized by Genetic Abnormalities of ALK1
1Not Yet RecruitingTreatmentEGFR Negative Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Stage IV Non-Small Cell Lung Cancer1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Adult Solid Neoplasm / Advanced Malignant Solid Neoplasm / ALK positive / Pancreatic Adenocarcinoma Metastatic / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1RecruitingTreatmentALK-positive NSCLC1
1RecruitingTreatmentCancers / Neuroblastomas1
1RecruitingTreatmentHead and Neck Carcinoma / Lung Cancers1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Systemic Anaplastic Large Cell Lymphoma1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAdenocarcinoma Lung Cancer / Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2CompletedTreatmentTumors With Aberrations in ALK or ROS11
2Not Yet RecruitingTreatmentNon-small Cell Lung Cancer Harboring ROS1 Rearrangement1
2RecruitingTreatmentALK Fusion Protein Expression / BRAF wt Allele / Invasive Skin Melanoma / Melanoma / MET Fusion Gene Positive / NRAS wt Allele / NTRK1 Fusion Positive / NTRK2 Fusion Positive / NTRK3 Fusion Positive / RET Fusion Positive / ROS1 Fusion Positive / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v71
2RecruitingTreatmentALK-positive Non-small Cell Lung Cancer / ALK-positive Non-small Cell Lung Cancer (NSCLC) / ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges1
2RecruitingTreatmentALK-positive Non-small Cell Lung Cancer1
2RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of the Pancreas / Cholangiocarcinomas / Colorectal Adenocarcinoma / Gastric Adenocarcinoma / Hepatocellular Adenocarcinoma1
2RecruitingTreatmentAdvanced Melanoma / Melanoma / Unresectable Melanoma1
2RecruitingTreatmentCholangiocarcinomas1
2RecruitingTreatmentLocally Advanced Anaplastic, Undifferentiated Thyroid Cancer / Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer / Metastatic Anaplastic Thyroid Cancer / Metastatic Anaplastic/Undifferentiated Thyroid Cancer1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentTumors With Aberrations in ALK1
2WithdrawnTreatmentMalignancies, Hematologic1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
4RecruitingTreatmentALK Positive Malignancies1
Not AvailableAvailableNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingNot AvailableAnaplastic Lymphoma Kinase-positive / Carcinoma Non-small-cell Lung1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral150 mg
CapsuleOral150 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8039474No2010-06-292030-06-29Us
US8703787No2012-02-022032-02-02Us
US8377921No2007-11-202027-11-20Us
US8039479No2010-06-292030-06-29Us
US7893074No2006-04-252026-04-25Us
US9309229No2012-01-182032-01-18Us
US7153964No2001-02-262021-02-26Us
US7964592No2007-01-132027-01-13Us
US8399450No2007-11-202027-11-20Us
US8835430No2003-01-312023-01-31Us
US9018204No2003-01-312023-01-31Us
US8188276No2003-01-312023-01-31Us
US9416112No2003-01-312023-01-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
pKa9.7 and 4.1FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.00222 mg/mLALOGPS
logP5.23ALOGPS
logP5.81ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.58ChemAxon
pKa (Strongest Basic)10.07ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area105.24 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity153.86 m3·mol-1ChemAxon
Polarizability61.33 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Benzenesulfonyl compounds / Phenoxy compounds / Phenol ethers / Aniline and substituted anilines / Toluenes / Alkyl aryl ethers / Aminopyrimidines and derivatives / Aralkylamines / Halopyrimidines / Imidolactams
show 9 more
Substituents
Phenylpiperidine / Benzenesulfonyl group / Phenoxy compound / Phenol ether / Aniline or substituted anilines / Alkyl aryl ether / Aminopyrimidine / Halopyrimidine / Toluene / Aralkylamine
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis a...
Gene Name
ALK
Uniprot ID
Q9UM73
Uniprot Name
ALK tyrosine kinase receptor
Molecular Weight
176440.535 Da
References
  1. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, Gray NS, Warmuth M: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. Epub 2006 Dec 21. [PubMed:17185414]
  2. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY: Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26. [PubMed:23742252]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Components:

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on May 11, 2015 16:20 / Updated on August 15, 2018 09:56